Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662492 · ClinicalTrials.gov registry record · Phase 3
A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT01662492 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 125 participants.
The verdict
NCT01662492, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
Interventions
- DRUG Placebo (Normal Saline)
- BIOLOGICAL Botulinum toxin type A Dose 1
- BIOLOGICAL Botulinum toxin type A Dose 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662492
The ClinicalTrials.gov registry entry for NCT01662492 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo (Normal Saline) is the first listed.
NCT01662492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662492 about?
NCT01662492 is a clinical study titled "A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine". To evaluate the efficacy and safety of Botulinum Toxin Type A versus placebo (normal saline) as headache prophylaxis in adolescents (children 12 to 17) with chronic migraine.
What is the current status of trial NCT01662492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2012-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01662492?
The interventions under investigation include: Placebo (Normal Saline) (DRUG), Botulinum toxin type A Dose 1 (BIOLOGICAL), Botulinum toxin type A Dose 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01662492?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.